| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Narsoplimab manufacturers
- Narsoplimab
-
- $263.00
-
2026-07-27
- CAS:2108782-45-0
- Purity: 98.56% (SEC-HPLC)
- Supply Ability: 10g
|
| | Narsoplimab Basic information |
| Product Name: | Narsoplimab | | Synonyms: | Narsoplimab;Research Grade Narsoplimab(DHA04501);Narsoplimab (anti-MASP2);OMS 721;Research Grade Narsoplimab | | CAS: | 2108782-45-0 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Narsoplimab Structure]() |
| | Narsoplimab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Narsoplimab Usage And Synthesis |
| Uses | Narsoplimab (OMS 721) is a high-affinity fully human immunoglobulin gamma 4 (IgG4) monoclonal antibody that binds MASP-2 and blocks lectin pathway activation. Narsoplimab can be used in research of hematopoietic stem-cell transplantation and SARS-CoV-2[1]. | | in vivo | Narsoplimab (10 mg/kg; i.v.; WT and Masp2-/- (KO) mice) decreases percentage of lymphocytes (Lym%) and increases percentage of neutrophils (Neu%)[1]. | Animal Model: | WT and Masp2-/- (KO) mice (C57BL/6N, female, 12-15 weeks old)[1] | | Dosage: | 10 mg/kg | | Administration: | Intravenous injection | | Result: | Decreased percentage of lymphocytes (Lym%) and an increased percentage of neutrophils (Neu%). |
| | References | [1] Gao T, et, al. Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduct Target Ther. 2022 Sep 14;7(1):318. DOI:10.1038/s41392-022-01133-5 |
| | Narsoplimab Preparation Products And Raw materials |
|